1.
Is the information provided by amino acid PET radiopharmaceuticals clinically equivalent in gliomas?
by Verger, A
European journal of nuclear medicine and molecular imaging, 2017, Vol.44 (8), p.1408-1410
2.
IDH mutation is paradoxically associated with higher 18F-FDOPA PET uptake in diffuse grade II and grade III gliomas
by Verger, A
European journal of nuclear medicine and molecular imaging, 2017, Vol.44 (8), p.1306-1311
3.
Outcome of Gamma Knife Radiosurgery in 82 Patients with Acromegaly: Correlation with Initial Hypersecretion
by Castinetti, Frédéric
The journal of clinical endocrinology and metabolism, 2005, Vol.90 (8), p.4483-4488
4.
Comparison of Seven Serum Thyroglobulin Assays in the Follow-Up of Papillary and Follicular Thyroid Cancer Patients
by Schlumberger, M
The journal of clinical endocrinology and metabolism, 2007, Vol.92 (7), p.2487-2495
5.
Adrenal Myelolipoma: An Unusual Cause of Bilateral Highly 18F-FDG-Avid Adrenal Masses
by Castinetti, F
The journal of clinical endocrinology and metabolism, 2012, Vol.97 (8), p.2577-2578
6.
European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma...
by Taieb, D
European journal of nuclear medicine and molecular imaging, 2019, Vol.46 (10), p.2112-2137
7.
Limited Value of 18F-F-DOPA PET to Localize Pancreatic Insulin-Secreting Tumors in Adults with Hyperinsulinemic Hypoglycemia
by Tessonnier, L
The journal of clinical endocrinology and metabolism, 2010, Vol.95 (1), p.303-307
8.
Iodine Biokinetics and Radioiodine Exposure after Recombinant Human Thyrotropin-Assisted Remnant Ablation in Comparison with Thyroid Hormone Withdrawal
by Taïeb, D
The journal of clinical endocrinology and metabolism, 2010, Vol.95 (7), p.3283-3290
9.
Value of 123I/99mTc-sestamibi parathyroid scintigraphy with subtraction SPECT/CT in primary hyperparathyroidism for directing minimally invasive parathyroidectomy
by Asseeva, Pauline
The American journal of surgery, 2019, Vol.217 (1), p.108-113
10.
EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma
by Taieb, D
European journal of nuclear medicine and molecular imaging, 2012, Vol.39 (12), p.1977-1995
11.
IDH mutation is paradoxically associated with higher 18.sup.F-FDOPA PET uptake in diffuse grade II and grade III gliomas
by Verger, A
European journal of nuclear medicine and molecular imaging, 2017, Vol.44 (8), p.1306
12.
CIP4 is a new ArgBP2 interacting protein that modulates the ArgBP2 mediated control of WAVE1 phosphorylation and cancer cell migration
by Roignot, J
Cancer letters, 2009, Vol.288 (1), p.116-123
13.
Does 18F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours?
by Tessonnier, L
European journal of nuclear medicine and molecular imaging, 2008, Vol.35 (11), p.2018-2025
14.
IDH mutation is paradoxically associated with higher 18F-FDOPA PET uptake in diffuse grade II and grade III gliomas
by Verger, A.
European journal of nuclear medicine and molecular imaging, 2017, Vol.44 (8), p.1306-1311
15.
Editorial: Energy Constraints and Lifetime Performance in Wireless Sensor Networks
by Li, Bo
Mobile networks and applications, 2005, Vol.10 (6), p.807-809
16.
How do French nuclear physicians deal with ethical aspects of ă communication results to patients after PET performed for oncological ă indications? A national french survey
by Gonzalez, S.
European journal of nuclear medicine and molecular imaging, 2016, Vol.43 (1), p.S521
17.
Lack of efficacy of recombinant human thyrotropin versus thyroid hormone withdrawal for radioiodine therapy imaging in a patient with differentiated thyroid carcinoma lung metastas...
by Taïeb, D
Thyroid (New York, N.Y.), 2004, Vol.14 (6), p.465-467
18.
Renaissance of (18)F-FDG positron emission tomography in the imaging of pheochromocytoma/paraganglioma
by Taieb, D
The journal of clinical endocrinology and metabolism, 2014, Vol.99 (7), p.2337-2339
19.
Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial
by Mir, Olivier, MD
The lancet oncology, 2016, Vol.17 (12), p.1732-1742
20.
IDH mutation is paradoxically associated with higher 18 F-FDOPA PET uptake in diffuse grade II and grade III gliomas
by Verger, A
European journal of nuclear medicine and molecular imaging, 2017, Vol.44 (8), p.1306
